Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT ID: NCT02101203

Last Updated: 2015-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2014-10-31

Brief Summary

A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive activity of sexual inhibitory mechanisms.

This is a 2-arm placebo and Lybridos (0.5 mg testosterone + buspirone 10 mg) extension to study EB90 (Clinical Study Protocol EB90a, version 3.0, 07 June 2013).

In the present study, the efficacy of Lybridos will be evaluated in the domestic setting in healthy female subjects with HSDD and maladaptive activity of sexual inhibitory mechanism(s). Sexual satisfaction and other aspects of sexual functioning will be measured within 24 hours after each sexual activity. The following hypotheses will be tested:

Lybridos, as compared to placebo, will significantly increase the number of satisfying sexual events.

Objectives:

To investigate the efficacy of Lybridos as compared to placebo in increasing the number of satisfactory sexual episodes in healthy female subjects with hypoactive sexual desire disorder (HSDD) and maladaptive activity of sexual inhibitory mechanisms

• To identify the optimal dose of Lybridos to take into phase 3 clinical development
• To confirm that Lybridos has superior efficacy as compared to testosterone alone and to buspirone alone
• To evaluate the effect of Lybridos as measured by scales of sexual satisfaction and/or sexual desire/arousal
• To evaluate the safety profile of Lybridos

Detailed Description

None entered

Conditions

Hypoactive Sexual Desire Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo

40 subjects administered placebo

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Testosterone + Buspirone

40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride

Group Type: EXPERIMENTAL

0.5 mgTestosterone + 10 mg Buspirone

Intervention Type: DRUG

A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, "on demand") throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).

Interventions

Placebo

Intervention Type: DRUG

0.5 mgTestosterone + 10 mg Buspirone

A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, "on demand") throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).

Intervention Type: DRUG

Other Intervention Names

Solid Oral Dosage. Maximum every other day (on an as needed basis); Solid Oral Dosage. Maximum every other day (on an as needed basis)

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria:

1. Provision of written informed consent

2. Females between 21 and 70 years of age, inclusive, pre or postmenopausal, with HSDD (comorbidity with female sexual arousal disorder [FSAD] and/or female orgasmic disorder [FOD; only as secondary diagnosis] is allowed). The diagnosis of HSDD will be established by a trained health care professional.

3. Maladaptive activity of sexual inhibitory mechanism(s) (see appendix 4 for definition)

4. Be involved in a stable relationship and have a partner who will be at home for the majority of the study duration

5. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant

Exclusion Criteria

Subjects who meet any of the following criteria are not eligible to participate in the study:

Cardiovascular Conditions

1. Any underlying cardiovascular condition, including unstable angina pectoris, that would preclude sexual activity

2. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure > 90 mmHg. For subjects ≥ 60 years old and without diabetes mellitus, familial hypercholesterolemia, or cardiovascular disease: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg

3. Systolic blood pressure ≤ 90 mmHg and/or diastolic blood pressure ≤ 50 mmHg Gynecological and Obstetric Conditions

4. Use of any contraceptive containing anti-androgens (e.g. Cyproteron acetate) or (anti)androgenic progestogens (drospirenone, dienogest, chlormadinone acetate and norgestrel)

5. Use of any contraceptive or hormone replacement therapy (HRT) containing more than 50 μg/day of estrogen

6. Positive test result for Chlamydia or gonorrhea

7. Pregnancy or intention to become pregnant during this study (Note: A urine pregnancy test will be performed in all women of child bearing potential prior to the administration of study medications.)

8. Lactating or delivery in the previous 6 months prior to signing Informed Consent Form

9. Significant abnormal Pap smear in the previous 12 months prior to signing Informed Consent Form

10. History of bilateral oophorectomy

11. Other unexplained gynecological complaints, such as clinically relevant abnormal uterine bleeding patterns

12. Perimenopausal status (cycle shortening/irregular menstrual bleeding in the last 12 consecutive months and/or occurrence of vasomotor symptoms (e.g. hot flashes, night sweating) in combination with elevated FSH levels (>40 IU/L) for women from age 40 onwards; in women with a history of hysterectomy perimenopausality can be assessed by FSH levels (>40 IU/L) and/or vasomotor symptoms Other Medical Conditions

13. Liver and/or renal insufficiency (aspartate aminotransferase, alanine aminotransferase and gamma glutamyltransferase > 3 times the upper limit of normal and/or estimated glomerular filtration rate (eGFR) < 60.00 mL/min based on the Cockcroft Gault formula)

14. Any current endocrine disease or endocrinopathy (e.g. uncontrolled thyroid dysfunction) as determined by medical history, basic physical examination and/or laboratory values significantly outside the normal range of the central laboratory; or uncontrolled diabetes mellitus(HbA1c > 7.5%)

15. Free- and/or total testosterone levels outside the upper limit of the reference range of the central laboratory (free testosterone: > 1.1 ng/dL, and total testosterone > 80 ng/dL)

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Emotional Brain NY Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

San Diego Sexual Medicine

San Diego, California, United States

Meridien Research

Bradenton, Florida, United States

Compass Research

Orlando, Florida, United States

Meridien Research

St. Petersburg, Florida, United States

Comprehensive Clinical Trials LLC

West Palm Beach, Florida, United States

Annapolis Sexual Wellness Center

Annapolis, Maryland, United States

Maryland Center for Sexual Wellness

Lutherville, Maryland, United States

Maryland Primary Care Physicians

Queenstown, Maryland, United States

NECCR Fall River LLC

Fall River, Massachusetts, United States

Philadelphia Clinical Research, LLC

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

EB90a extension

Identifier Type: -

Identifier Source: org_study_id